Demographics of eligible patients and characteristics of reported symptoms
| All patients N=998 | Phase 1 N=633 | Phase 2 N=365 | |
| Age, years (range) | 59.7 (18–90) | 59.3 (18–90) | 58.8 (18–90) |
| Sex | |||
| Male | 409 (41%) | 244 (39%) | 165 (45%) |
| Female | 578 (58%) | 385 (61%) | 193 (53%) |
| Unrecorded | 11 (1%) | 4 (1%) | 7 (2%) |
| Race | |||
| Caucasian | 599 (60%) | 335 (53%) | 264 (72%) |
| Asian/Asian British | 189 (19%) | 161 (25%) | 28 (8%) |
| Black/African/Caribbean/Black British | 100 (10%) | 73 (12%) | 27 (7%) |
| Arab | 30 (3%) | 17 (3%) | 13 (4%) |
| Other | 60 (6%) | 31 (5%) | 29 (8%) |
| Unrecorded | 20 (2%) | 16 (3%) | 4 (1%) |
| Current smoker | 120 (12%) | 72 (11%) | 48 (13%) |
| Oral intake <5 hours | 798 (80%) | 458 (72%) | 340 (93%) |
| Duration of main symptom(s) | |||
| Today | 234 (25%) | 139 (22%) | 95 (26%) |
| Recently (within 8 weeks) | 351 (38%) | 241 (38%) | 110 (30%) |
| Chronic | 172 (19%) | 112 (18%) | 60 (16%) |
| Unrecorded | 241 (26%) | 141 (22%) | 100 (28%) |
| Patients reporting | N=921* | N=586 | N=335 |
| ≥1 UGI symptom | 822 (89%) | 533 (91%) | 289 (86%) |
| ≥1 LGI symptom | 608 (66%) | 397 (68%) | 211 (63%) |
| Single symptom reported | 165 (18%) | 110 (19%) | 55 (16%) |
| UGI symptoms(s) warranting urgent referral† | 152 (17%) | 98 (17%) | 54 (16%) |
| UGI symptom(s) warranting non-urgent referral† | 306 (33%) | 199 (34%) | 107 (32%) |
| LGI symptoms(s) warranting urgent referral† | 289 (31%) | 178 (30%) | 111 (33%) |
*Symptoms were unrecorded in 77 patients, however for 44 of these patients the ‘duration of symptoms’ was recorded.
†Symptom(s) warranting urgent direct access endoscopic or radiological referral or urgent 2WW referral as per NICE guidelines for UGI (including pancreatic cancer) and LGI cancer.8 9
LGI, lower gastrointestinal; NICE, National Institute for Health and Care Excellence; UGI, upper gastrointestinal; 2WW, 2 week wait.